Privately-held US biotech Teon Therapeutics has announced the appointment of Serge Messerlian as chief executive and member of the board of directors.
Mr Messerlian will assume the role from co-founder, acting CEO and chief scientific officer (CSO), Dr Lina Yao, who remains as CSO. Dr Yao will continue as a member of the board of directors.
Mr Messerlian brings to the role significant experience in the industry, across a range of roles and therapeutic areas including hematology, oncology, immunology, and rare diseases. He joins Teon from Janssen Oncology US, a subsidiary of Johnson & Johnson (NYSE: JNJ), where he served as president and set the strategic direction for the organization and its key brands across hematology and solid tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze